NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Applauds FDA Forward-Looking Decision on Reduced Risk Tobacco Format
Global innovator in drug delivery platforms Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) today announced that the Food and Drug Administration ("FDA"), for the first time ever, has authorized the marketing of oral nicotine products through the Modified Risk Tobacco Product pathway. According to the update, this pathway includes product categories that could benefit from Lexaria's technology. The FDA-authorized product format is in the tobacco pouch category, similar to a mini tea-bag that is held in the mouth from which the nicotine within is absorbed. Unlike chewing tobacco, there is no need to spit. Significantly, because there is no combustion, heating…







